Completed PHASE2 INTERVENTIONAL NCT00099489

Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of AVONEX When Used in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Sponsor: Biogen

Conditions Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Interventions Interferon Beta-1a

Updated 5 times since 2017 Last updated: Mar 4, 2010 Started: Feb 29, 2004 Primary completion: Feb 28, 2006 Completion: Feb 28, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chronic Inflammatory Demyelinating Polyradiculoneuropathy and is currently completed. Biogen leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biogen

Data source: Biogen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boston, United States , Dallas, United States , Fitzroy, Australia , Jacksonville, United States , Kansas City, United States , Liverpool, Australia , London, Canada , London, United Kingdom , Miami, United States , Minneapolis, United States and 9 more locations